4-aminopyrimidine derivative as CXCR4 inhibitor, and applications thereof

A technology that inhibits activity, alkyl, and is used in anti-inflammatory agents, antiviral agents, drug combinations, etc.

Active Publication Date: 2019-04-02
CGENETECH (SUZHOU CHINA) CO LTD
View PDF11 Cites 2 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Although AMD070 entered the second phase of clinical trials, the clinical tria

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • 4-aminopyrimidine derivative as CXCR4 inhibitor, and applications thereof
  • 4-aminopyrimidine derivative as CXCR4 inhibitor, and applications thereof
  • 4-aminopyrimidine derivative as CXCR4 inhibitor, and applications thereof

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0065] Heterocyclic compound A1, which is synthesized by the following method:

[0066]

[0067] 1) Synthesis of intermediate A1-2:

[0068] Intermediate A1-1 (280mg, 1.9mmol, please refer to WO2016128529 for synthesis literature) was dissolved in dichloromethane (10mL), and thionyl chloride (280mg, 2.3mmol) was added dropwise under ice-cooling, stirring was continued overnight, and sodium bicarbonate was added The solution was extracted three times with dichloromethane (50 mL), and the dichloromethane phase was dried and spin-dried to obtain a pale yellow oil (180 mg, 58%).

[0069] 2) Synthesis of intermediate A1-4:

[0070] Intermediate A1-3 (160mg, 1mmol, see WO2006026703 for synthesis literature), Intermediate A1-2 (170mg, 1.05mmol), potassium iodide (16mg, 0.1mmol) and N, N-diisopropylethylamine (320mg, 2.5mmol) was dissolved in 10mL acetonitrile, stirred overnight at room temperature, added 100mL dichloromethane and 50mL sodium bicarbonate aqueous solution for extr...

Embodiment 2

[0074] According to the synthesis method of Example 1, the corresponding amines were used to replace N-methylpiperazine in the last step to obtain heterocyclic compounds A2, A5, A6, A22-A26, A39 and A60.

Embodiment 3

[0076] Heterocyclic compound A3, which is synthesized by the following method:

[0077]

[0078] 1) Synthesis of Intermediate A3-2:

[0079] Ethyl 4-chloroacetoacetate (13g, 79mmol), S-methylisothiourea sulfate (20g, 72mmol), dissolved in 200mL of water, added sodium carbonate (11.5g, 108mmol), stirred overnight at room temperature, added 6N HCl The pH was adjusted to be acidic, and a solid was precipitated, which was filtered and dried to obtain the product (11.1 g, 73%) as a white solid.

[0080] 2) Synthesis of intermediate A3-3:

[0081] Intermediate A3-2 (2.8g, 14.7mmol) was dissolved in 10mL phosphorus oxychloride, stirred at 100°C for 1h, spin-dried, added 100mL ethyl acetate and 100mL sodium bicarbonate aqueous solution for extraction, ethyl acetate was dried and spin-dried. The residue was purified by column chromatography (ethyl acetate:petroleum ether=100:3) to obtain the product (2.4 g, 80%) as a yellow oily liquid.

[0082] 3) Synthesis of Intermediate A3-4:...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The present invention provides a heterocyclic compound having CXCR4 signaling pathway inhibitory activity, and a pharmaceutically acceptable salt, an isotope, an isomer and a crystal form structure thereof, wherein the compound has a structure represented by a general formula I defined in the specification. The present invention further provides applications of the heterocyclic compound having CXCR4 signaling pathway inhibitory activity. According to the present invention, the heterocyclic compound having CXCR4 signaling pathway inhibitory activity, as the effective antagonist of the CXCR4 signaling pathway, can be used for treating or preventing diseases responsive to CXCR4 receptor antagonism.

Description

technical field [0001] The present invention relates to a heterocyclic compound having CXCR4 inhibitory activity, a composition comprising the compound, a method for preparing the compound, and the use of the compound in medicine, especially for the treatment of CXCR4-responsive The present invention also relates to the use of said compounds in stem cell harvesting methods for diseases antagonized by the body, such as cancer, cancer metastasis, HIV, HIV-related diseases, brain inflammation, diabetic retinopathy, age-related macular degeneration and retinal angiogenesis Uses, including, for example, facilitating the release and mobilization of stem cells, including hematopoietic stem cells, non-hematopoietic stem cells, and progenitor stem cells, prior to harvesting. The invention belongs to the technical field of medicine. Background technique [0002] CXCR4 belongs to seven transmembrane G-protein coupled receptors (GPCR), and its endogenous ligand is chemokine SDF-1 (stro...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): C07D401/12C07D401/14C07D405/14C07D487/04C07D491/052A61K31/506A61K31/5377A61K31/551A61P35/00A61P31/18A61P3/10A61P29/00A61P27/02A61P7/00
CPCA61P3/10A61P7/00A61P27/02A61P29/00A61P31/18A61P35/00C07D401/12C07D401/14C07D405/14C07D487/04C07D491/052
Inventor 张小虎郑计岳马海阔
Owner CGENETECH (SUZHOU CHINA) CO LTD
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap